CN102573791B - 改进的制剂 - Google Patents

改进的制剂 Download PDF

Info

Publication number
CN102573791B
CN102573791B CN201080046305.6A CN201080046305A CN102573791B CN 102573791 B CN102573791 B CN 102573791B CN 201080046305 A CN201080046305 A CN 201080046305A CN 102573791 B CN102573791 B CN 102573791B
Authority
CN
China
Prior art keywords
fluticasone propionate
formulation
dose
amount
aerosol formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201080046305.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN102573791A (zh
Inventor
R·米勒-瓦尔茨
L-M·菲格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jagotec AG
Original Assignee
Jagotec AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41462451&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102573791(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jagotec AG filed Critical Jagotec AG
Publication of CN102573791A publication Critical patent/CN102573791A/zh
Application granted granted Critical
Publication of CN102573791B publication Critical patent/CN102573791B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201080046305.6A 2009-10-16 2010-10-15 改进的制剂 Active CN102573791B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0918150.4 2009-10-16
GBGB0918150.4A GB0918150D0 (en) 2009-10-16 2009-10-16 Improved formulations
PCT/EP2010/065569 WO2011045429A1 (en) 2009-10-16 2010-10-15 Improved formulations

Publications (2)

Publication Number Publication Date
CN102573791A CN102573791A (zh) 2012-07-11
CN102573791B true CN102573791B (zh) 2017-09-22

Family

ID=41462451

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080046305.6A Active CN102573791B (zh) 2009-10-16 2010-10-15 改进的制剂

Country Status (25)

Country Link
US (2) US20120263766A1 (enExample)
EP (2) EP2488157B1 (enExample)
JP (2) JP5818801B2 (enExample)
CN (1) CN102573791B (enExample)
AU (1) AU2010305695B2 (enExample)
BR (1) BR112012008969B1 (enExample)
CA (1) CA2776845C (enExample)
CL (1) CL2012000948A1 (enExample)
CY (1) CY1123918T1 (enExample)
DK (1) DK2488157T3 (enExample)
ES (1) ES2859629T3 (enExample)
GB (1) GB0918150D0 (enExample)
HR (1) HRP20210379T1 (enExample)
HU (1) HUE054030T2 (enExample)
IL (2) IL219162A0 (enExample)
LT (1) LT2488157T (enExample)
MX (1) MX372991B (enExample)
NZ (1) NZ599900A (enExample)
PL (1) PL2488157T3 (enExample)
PT (1) PT2488157T (enExample)
RS (1) RS61430B1 (enExample)
SI (1) SI2488157T1 (enExample)
SM (1) SMT202100150T1 (enExample)
WO (1) WO2011045429A1 (enExample)
ZA (1) ZA201202595B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ528640A (en) * 2001-03-30 2004-06-25 Jagotec Ag Medical aerosol formulations
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0918149D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
GB0918150D0 (en) * 2009-10-16 2009-12-02 Jagotec Ag Improved formulations
JP6335798B2 (ja) * 2012-02-28 2018-05-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規噴射剤含有チオトロピウム製剤
JP2015512929A (ja) * 2012-04-11 2015-04-30 シプラ・リミテッド 医薬組成物
GB201321712D0 (en) * 2013-12-09 2014-01-22 Pharmachemie Bv Dry Powder Inhaler
CN105963282B (zh) * 2016-05-04 2019-04-19 四川普锐特医药科技有限责任公司 一种医用定量吸入气雾剂
WO2018059390A1 (zh) * 2016-09-29 2018-04-05 广东东阳光药业有限公司 药物组合物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002030394A2 (en) * 2000-10-09 2002-04-18 3M Innovative Properties Company Medicinal aerosol formulations
WO2002078671A1 (de) * 2001-03-30 2002-10-10 Jagotec Ag Medizinische aerosolformulierungen
CN1452479A (zh) * 2000-05-22 2003-10-29 奇斯药制品公司 用于加压计量吸入器的稳定药用溶液制剂
CN101389341A (zh) * 2006-04-21 2009-03-18 奇斯药制品公司 用于加压计量吸入器的药物溶液制剂

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596260B1 (en) 1993-08-27 2003-07-22 Novartis Corporation Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol
AU718263B2 (en) 1995-04-14 2000-04-13 Smithkline Beecham Corporation Metered dose inhaler for salmeterol
AU710382B2 (en) 1995-04-14 1999-09-16 Glaxo Wellcome Inc. Metered dose inhaler for albuterol
JPH101442A (ja) * 1996-06-12 1998-01-06 Taisho Pharmaceut Co Ltd 鼻炎用点鼻薬
CZ295460B6 (cs) * 1997-03-20 2005-08-17 Schering Corporation Způsob výroby aglomerátů a jednotková dávka farmakologicky aktivní látky je obsahující
GB9903759D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
US20030207057A1 (en) 2000-09-18 2003-11-06 Britto Ignatius Loy Metered dose inhaler can coated two or more times with fluorocarbon polymers
US6667344B2 (en) * 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
GB0201400D0 (en) * 2002-01-22 2002-03-13 Glaxo Group Ltd Novel apparatus and process
WO2004019985A1 (en) * 2002-08-29 2004-03-11 Cipla Ltd Pharmaceutical products and compositions comprising specific anticholinergic agents, beta-2 agonists and corticosteroids
GB0323684D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0327727D0 (en) * 2003-11-28 2003-12-31 Quadrant Drug Delivery Ltd Viral microparticles
GB0410399D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0918150D0 (en) * 2009-10-16 2009-12-02 Jagotec Ag Improved formulations

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1452479A (zh) * 2000-05-22 2003-10-29 奇斯药制品公司 用于加压计量吸入器的稳定药用溶液制剂
WO2002030394A2 (en) * 2000-10-09 2002-04-18 3M Innovative Properties Company Medicinal aerosol formulations
WO2002078671A1 (de) * 2001-03-30 2002-10-10 Jagotec Ag Medizinische aerosolformulierungen
CN101389341A (zh) * 2006-04-21 2009-03-18 奇斯药制品公司 用于加压计量吸入器的药物溶液制剂

Also Published As

Publication number Publication date
WO2011045429A1 (en) 2011-04-21
CN102573791A (zh) 2012-07-11
DK2488157T3 (da) 2021-01-25
ES2859629T3 (es) 2021-10-04
EP2488157B1 (en) 2020-12-30
NZ599900A (en) 2014-11-28
HRP20210379T1 (hr) 2021-04-16
BR112012008969A2 (pt) 2020-06-23
JP2016040286A (ja) 2016-03-24
BR112012008969B1 (pt) 2021-07-06
ZA201202595B (en) 2023-07-26
SMT202100150T1 (it) 2021-05-07
US20170281529A1 (en) 2017-10-05
IL269369A (en) 2019-11-28
CY1123918T1 (el) 2022-05-27
JP5818801B2 (ja) 2015-11-18
AU2010305695A1 (en) 2012-05-03
PL2488157T3 (pl) 2021-06-28
HUE054030T2 (hu) 2021-08-30
EP3811928A1 (en) 2021-04-28
RS61430B1 (sr) 2021-03-31
PT2488157T (pt) 2021-02-05
MX372991B (es) 2020-06-18
CA2776845A1 (en) 2011-04-21
MX2012004338A (es) 2012-08-01
SI2488157T1 (sl) 2021-02-26
GB0918150D0 (en) 2009-12-02
CA2776845C (en) 2018-04-24
LT2488157T (lt) 2021-02-10
JP2013507429A (ja) 2013-03-04
AU2010305695B2 (en) 2014-07-10
IL219162A0 (en) 2012-06-28
US20180296468A2 (en) 2018-10-18
CL2012000948A1 (es) 2012-12-14
US20120263766A1 (en) 2012-10-18
EP2488157A1 (en) 2012-08-22

Similar Documents

Publication Publication Date Title
CN102573791B (zh) 改进的制剂
EP2515855B3 (en) Combination therapy for COPD
KR101311662B1 (ko) 압축계량된 도스흡입기용 약제용액제제
CN102665678B (zh) 用于copd的联合治疗
JP2017507168A (ja) グリコピロニウム臭化物およびホルモテロールの組合せの安定な加圧エアゾール溶液組成物
AU2012358475B2 (en) An inhalable medicament comprising tiotropium
WO2005034911A1 (en) Aerosol formulations comprising formoterol fumarate dihydrate, a propellant,ethanol and optionally a steroid,where the formoterol fumarate dihydrate has a water content of 4.8-4.28% by weight
JP7203701B2 (ja) 改善された医薬エアゾール製剤
UA123231C2 (uk) Комбінована терапія для хохл
SK25399A3 (en) Chlorofluorocarbon-free mometasone furoate aerosol formulations
DK2727582T3 (en) Pharmaceutical aerosol formulations of formoterol and beclomethasone dipropionate
AU2013203244B2 (en) Improved formulations
HK1173076B (en) Improved formulations
HK1173076A (en) Improved formulations

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant